Media Articles Related to Nucynta (Tapentadol)
Sufentanil Hybrid Receives CHMP Nod for Post-Op Pain
Source: Medscape General Surgery Headlines [2015.07.24]
The new product, Zalviso, is similar to another sufentanil-containing anesthetic-analgesic that has been available in the Netherlands for decades.
Preventing knee pain in at-risk adults with diabetes
Source: Arthritis / Rheumatology News From Medical News Today [2015.07.24]
UD-led study assesses impact of intensive diet/exercise programKnee pain in older adults, often caused by osteoarthritis, usually means more visits to the doctor and also can be a harbinger of...
US South Asians more reluctant to seek medication for pain
Source: Pain / Anesthetics News From Medical News Today [2015.07.24]
Health care workers should be culturally aware when caring for patients and families from the South Asian regionWhen compared with other ethnicities, Asians are the most unsatisfied with the...
Inhaled Cannabis Promising for Painful Diabetic Neuropathy
Source: Medscape NeurologyHeadlines [2015.07.23]
A new study has shown that inhaled cannabis can blunt the pain of diabetic neuropathy without impairing cognitive function.
Medscape Medical News
Nondrug Tx Best for Fibromyalgia: The Pain Medicine News Report
Source: MedPage Today Neurology [2015.07.22]
(MedPage Today) -- Also, new evidence supports medical marijuana use for chronic pain.
Published Studies Related to Nucynta (Tapentadol)
Tapentadol potentiates descending pain inhibition in chronic pain patients with
diabetic polyneuropathy. 
decrease in noxious heat stimulation)... CONCLUSIONS: Tapentadol's analgesic effect in chronic pain patients with DPN is
Bowel function after tapentadol and oxycodone immediate release (IR) treatment in
patients with low back or osteoarthritis pain. 
OBJECTIVES: Constipation is a common side effect of opioid therapy. Tapentadol
immediate release (IR) was better tolerated than oxycodone IR in 2 clinical
trials involving patients with low back or osteoarthritis pain... DISCUSSION: Patient-reported bowel function associated with tapentadol IR
treatment was similar to that associated with placebo (10-d trial) and
significantly better than that associated with oxycodone IR treatment (10- and
Effect of tapentadol extended release on productivity: results from an analysis
combining evidence from multiple sources. 
OBJECTIVE: To compare the effects of tapentadol-extended release versus
oxycodone-controlled release for pain relief on productivity by combining
evidence from different sources.
Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. [2011.05]
INTRODUCTION: Two randomized, double-blind, placebo-controlled studies in acute and chronic pain treatment, powered to assess noninferiority of the efficacy of tapentadol immediate release (IR) (50 mg, 75 mg) versus oxycodone hydrochloride (HCl) IR (10 mg), established comparable efficacy of tapentadol IR with oxycodone HCl IR, and suggested tapentadol IR's improved gastrointestinal tolerability. The impact of these equianalgesic doses of tapentadol and oxycodone HCl on bowel function and gastrointestinal tolerability was then directly assessed in the current study, using a validated bowel function diary to comprehensively assess opioid-induced constipation symptoms and outcomes... CONCLUSION: Tapentadol IR (50 mg, 75 mg) consistently demonstrated superior gastrointestinal tolerability, including for the most commonly reported events, such as nausea, vomiting, and constipation at doses that provide comparable efficacy with oxycodone HCl IR 10 mg. These findings validate and extend the tolerability findings of the two earlier studies that established comparable efficacy of these tapentadol and oxycodone HCl doses.
Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. [2011.01]
CONCLUSIONS: Compared with placebo, tapentadol ER 100-250 mg bid provided a statistically significant difference in the maintenance of a clinically important improvement in pain 1 , 2 and was well-tolerated by patients with painful DPN.
Clinical Trials Related to Nucynta (Tapentadol)
Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin [Recruiting]
The main objective of the study is to evaluate the effectiveness, safety, and tolerability
of increasing doses of tapentadol prolonged release (PR) (500 mg per day) versus a
combination of tapentadol PR (300 mg per day) and pregabalin (to 300 mg per day) in subjects
requiring additional analgesia after titration to tapentadol PR 300 mg per day.
This is a clinical effectiveness trial designed to establish a link between anticipated
clinical outcomes and the clinical practice by means of selected measures of clinical and
subject reported outcomes. Since, severe low back pain with a neuropathic component, the
targeted study population, is frequently treated with a combination therapy (monotherapy is
often not effective enough) it is of interest to determine if tapentadol alone (combining 2
mechanisms of action in a single molecule) could be as effective as a combination of
tapentadol plus pregabalin. Furthermore, the tolerability profiles of monotherapy versus
combination are of interest.
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain [Recruiting]
Evaluate how NUCYNTA (tapentadol) immediate release (IR) compares with oxycodone IR in the
treatment of acute low back pain.
A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy [Recruiting]
The purpose of this study is to demonstrate the efficacy of at least 1 dose of tapentadol IR
50 mg and/or 75 mg versus placebo using the sum of pain intensity difference at 48 hours
(SPID48) to measure analgesic effect in Korean patients with acute pain following
A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain [Not yet recruiting]
A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain [Not yet recruiting]
Reports of Suspected Nucynta (Tapentadol) Side Effects
Drug Ineffective (20),
Confusional State (17),
Feeling Abnormal (17),
Withdrawal Syndrome (16),
Anxiety (14), more >>